Media Awareness
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
Originally Published: January 31, 2025
The Food and Drug Administration this week approved a new type of painkiller that doesn’t carry the risk of addiction or overdose associated with opioid medications.
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, the acting director of the FDA’s Center for Drug Evaluation and Research, said in a statement. “A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option.”
The FDA on Thursday approved Vertex Pharmaceuticals’ Journavx to treat moderate to severe acute pain in adults. Acute pain is short-term pain often caused by surgery, accident or injury.
The above content is a preview of content that appears on a third-party website. Stop the Judgment Project is not responsible for content appearing on third-party websites. Content may be subject to subscription fees.
Additional Media Stories
When One Pill Kills
Matt Capelouto’s daughter, Alex, was home for winter break from Arizona State University in 2019 ...
How Fentanyl Is Unfolding as One of America’s Greatest Tragedies
More than 100,000 people died from overdoses in the US in a 12-month period ending ...
Hollywood’s Sobering New Reality of Fentanyl Lacing
The ultra-powerful synthetic painkiller is increasingly mixed with other drugs, from cocaine to Xanax and ...
